The MarketWatch News Department was not involved in the creation of this content. -- Encore data to be presented demonstrating that cebranopadol displays significant and sustained pain reduction with ...
-Over 90% of patients in the study were opioid free through the end of multimodal treatment with JOURNAVX- -These data have been accepted for oral presentation at the American Academy of Pain Medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results